Q2 2026 13F · SEC CIK 1974915

Vestal Point Capital, LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $4.3B
Reported positions: 68
Top holdings a year, 3 yrs: +44.5%
Assets under management: $5.5B

Vestal Point Capital, LP is a hedge fund that reported 68 positions worth $4.3B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Biomarin Pharmaceutical Inc (BMRN, 8.1%), Neurocrine Biosciences Inc (NBIX, 7.4%), Abivax SA (ABVX, 7.3%). A portfolio copying its top holdings returned 44.5% a year over the last 3 years, against 18.8% for the S&P 500.

Vestal Point Capital, LP holdings largest 50 of 68 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Vestal Point Capital, LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
BMRNBiomarin Pharmaceutical Inc	8.1%	5.6%	6,025,000	+68.5%	$344.8M
NBIXNeurocrine Biosciences Inc	7.4%	4.6%	1,880,000	+50.4%	$316.8M
ABVXAbivax SA	7.3%	4.7%	2,349,443	+56.6%	$313.1M
UTHRUnited Therapeutics Corp Del	5.5%	1.2%	435,000	+480.0%	$235.7M
ELVNEnliven Therapeutics Inc	4.7%	3.6%	4,000,000	+23.1%	$203.0M
NRIXNurix Therapeutics Inc	4.6%	2.8%	8,050,000	+23.8%	$195.3M
BCAXBicara Therapeutics Inc	3.6%	3.0%	5,250,000	-3.2%	$155.9M
TSHATaysha Gene Therapies Inc	3.1%	2.2%	19,415,000	+7.9%	$132.2M
ARWRArrowhead Pharmaceuticals in	3.0%	4.0%	1,575,000	-30.8%	$128.4M
ABTAbbott Laboratories	3.0%	—	1,400,000	—	$127.0M
ZBHZimmer Biomet Holdings Inc	2.8%	—	1,400,000	—	$120.5M
IRONDisc Medicine Inc	2.6%	1.3%	1,550,000	+121.4%	$113.4M
GLUEMonte Rosa Therapeutics Inc	2.6%	1.7%	4,600,000	+27.7%	$111.3M
PODDInsulet Corp	2.4%	—	670,000	—	$102.0M
ASNDAscendis Pharma A/s	2.3%	—	375,000	—	$100.0M
AZNAstrazeneca PLC	2.0%	0.6%	450,000	+350.0%	$85.3M
SNYNFSanofi SA	2.0%	1.9%	2,000,000	+42.9%	$85.3M
RVMDRevolution Medicines Inc	2.0%	6.5%	450,000	-81.1%	$84.3M
BCRXBiocryst Pharmaceuticals Inc	1.9%	1.9%	8,300,000	+18.1%	$83.0M
DYNDyne Therapeutics Inc	1.8%	2.0%	3,375,000	-15.6%	$75.0M
NKTRNektar Therapeutics	1.6%	0.6%	1,000,000	+250.9%	$69.8M
GMEDGlobus Med Inc	1.6%	1.5%	850,000	+39.2%	$67.2M
TARSTarsus Pharmaceuticals Inc	1.5%	—	1,050,000	—	$66.1M
IMTXImmatics NV	1.5%	1.7%	6,175,000	+0.0%	$62.6M
TRVITrevi Therapeutics Inc	1.4%	0.7%	3,100,000	+43.1%	$57.8M
IMCRImmunocore Hldgs PLC	1.3%	2.3%	1,800,000	-34.9%	$57.1M
RGENRepligen Corp	1.3%	3.0%	400,000	-56.8%	$54.6M
BMYBristol-Myers Squibb Co	1.1%	1.7%	800,000	-20.0%	$46.1M
QUREUniqure NV	1.0%	—	935,000	—	$43.1M
XENEXenon Pharmaceuticals Inc	1.0%	1.0%	700,000	+9.4%	$42.3M
10919W405Bright Minds Biosciences Inc	0.9%	1.0%	545,000	+10.7%	$38.3M
MDGLMadrigal Pharmaceuticals Inc	0.8%	—	65,000	—	$34.9M
ALCAlcon Inc	0.8%	1.7%	500,000	-37.5%	$33.5M
MYGNMyriad Genetics Inc	0.8%	—	5,735,000	—	$32.7M
RAPPRapport Therapeutics Inc	0.7%	1.3%	730,000	-49.2%	$30.4M
CBIOCrescent Biopharma Inc	0.7%	0.8%	1,630,000	+8.7%	$29.3M
GEHCGe Healthcare Technologies I	0.7%	—	450,000	—	$28.8M
INSMInsmed Inc	0.6%	—	250,000	—	$26.7M
VKTXViking Therapeutics Inc	0.6%	0.8%	680,000	-25.6%	$26.5M
BBNXBeta Bionics Inc	0.6%	0.6%	1,600,000	-27.7%	$25.1M
REGNRegeneron Pharmaceuticals	0.6%	0.9%	40,000	+0.0%	$24.9M
SLDBSolid Bioscience Inc.	0.5%	1.0%	2,160,000	-56.8%	$21.6M
ANROAlto Neuroscience Inc	0.5%	1.3%	785,000	-62.0%	$20.7M
TRAXFirst Tracks Biotherapeutics	0.5%	—	1,013,000	—	$20.4M
LXEOLexeo Therapeutics Inc	0.5%	0.7%	4,320,000	-3.5%	$20.1M
SVRASavara Inc	0.4%	—	2,720,000	—	$16.8M
GLTODamora Therapeutics Inc	0.3%	—	575,000	—	$15.0M
SGPSpyglass Pharma Inc	0.3%	—	670,000	—	$14.9M
TECXTectonic Therapeutic Inc	0.3%	—	425,000	—	$14.6M
AVTXAvalo Therapeutics Inc	0.3%	—	775,000	—	$14.3M

What Vestal Point Capital, LP bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +107.0% /yr; S&P 500 +20.1%
3 years: +44.5% /yr; S&P 500 +18.8%
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$4.3B	68
Q1 2026	$3.6B	90
Q4 2025	$2.7B	75
Q3 2025	$2.2B	80
Q2 2025	$1.9B	72
Q1 2025	$1.4B	63
Q4 2024	$1.7B	73
Q3 2024	$1.3B	67
Q2 2024	$1.3B	60
Q1 2024	$1.2B	58
Q4 2023	$944.0M	48

Questions about Vestal Point Capital, LP's portfolio

What stocks does Vestal Point Capital, LP own?

Vestal Point Capital, LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 68 positions worth $4.3B. The largest are Biomarin Pharmaceutical Inc (BMRN) at 8.1%, Neurocrine Biosciences Inc (NBIX) at 7.4%, Abivax SA (ABVX) at 7.3%, United Therapeutics Corp Del (UTHR) at 5.5% and Enliven Therapeutics Inc (ELVN) at 4.7%.

What did Vestal Point Capital, LP buy last quarter?

In Q2 2026, Vestal Point Capital, LP added United Therapeutics Corp Del (UTHR) (+480.0% shares), Astrazeneca PLC (AZN) (+350.0% shares) and Nektar Therapeutics (NKTR) (+250.9% shares), compared with its Q1 2026 filing.

What did Vestal Point Capital, LP sell last quarter?

In Q2 2026, Vestal Point Capital, LP cut from its top 50 Apogee Therapeutics Inc (APGE), cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Scholar Rock Hldg Corp (SRRK), cut from its top 50 Vera Therapeutics Inc Class A (VERA), cut from its top 50 Terns Pharmaceuticals Inc (TERN), Revolution Medicines Inc (RVMD) (-81.1% shares), Alto Neuroscience Inc (ANRO) (-62.0% shares) and Solid Bioscience Inc. (SLDB) (-56.8% shares), compared with its Q1 2026 filing.

How has Vestal Point Capital, LP's portfolio performed?

A portfolio copying Vestal Point Capital, LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +44.5% a year over the last 3 years, against +18.8% for the S&P 500. Over 1 year: +107.0% against +20.1%.

When is Vestal Point Capital, LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Vestal Point Capital, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Vestal Point Capital, LP manage?

Vestal Point Capital, LP reported $5.5B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $4.3B.